The number of international patent applications for Chinese medicine has entered the top three in the world, but these problems are still difficult.

In the past five years, the number of international patent applications for pharmaceuticals in my country has entered the top three in the world, marking a significant increase in the intellectual property strength of Chinese pharmaceutical companies. However, the overall level of intellectual property rights in the domestic pharmaceutical industry is still relatively low compared to developed countries such as Europe and the United States, and the original innovation capabilities of Chinese pharmaceutical companies are relatively insufficient. How to break this "bottleneck" is still a major issue in China's pharmaceutical industry.

More than 50 patents newly expired drugs to achieve localization, a number of key biomedical materials and medical equipment to break foreign monopolies, health and health collaborative innovation system basically completed ...... In the recently held national health and health science and technology innovation work conference, China's pharmaceutical industry "Twelfth Five-Year Plan" period of independent innovation achievements have attracted widespread attention of the whole society. In the view of many heads of Chinese pharmaceutical enterprises, at the scientific and technological innovation conference of health and family planning system held again after 20 years, one of their most important achievements is that in the past five years, the number of international patent applications for Chinese medicine has entered the top three in the world, which not only marks a significant improvement in the intellectual property strength of Chinese pharmaceutical enterprises, It is also the "key to opening the door" for Chinese pharmaceutical enterprises to integrate into the international market and participate in the global industrial chain ".

In recent years, the rapid development of China's pharmaceutical industry has not only improved the level of domestic health care, but also demonstrated the "Chinese power" in the health field in front of the world ". For Chinese pharmaceutical companies, this is not only a boost from the external environment, but also an urgent need for the internal development of Chinese pharmaceutical companies.

The pharmaceutical industry is a high-investment, long-cycle industry, relying on research and development to master core technology patents, and promote the international registration and certification of patented drugs, which is the only way for the development of pharmaceutical enterprises.

Of course, the number of international patent applications has entered the top three in the world. In the final analysis, this is only an achievement in the sense of "book. For Chinese pharmaceutical companies, at present, under the background of the development of globalization, they are also facing obstacles that need to be overcome. "In recent years, the international biomedical industry has developed rapidly, but the domestic pharmaceutical industry as a whole

The level of intellectual property rights is low, and the original innovation capabilities of my country's pharmaceutical companies are relatively insufficient, and there is an urgent need for a master key that can open the cage. To break through the bottleneck of original innovation, the key is to realize the patent work of pharmaceutical enterprises from loose management to the construction and improvement of intellectual property strategic system. Only in this way can the innovation driven, transformation and upgrading of enterprises be realized. A perfect intellectual property management system is the most critical part of pharmaceutical enterprises and the basis of all original innovation work.

Due to the particularity of drugs, drug research and development takes a long time and costs a lot, ranging from more than 10 years to more than decades. Even if drugs are developed, they will have to go through multiple clinical trials in clinical application. It is difficult for general pharmaceutical companies to have this strength. Therefore, domestic enterprises can consider obtaining the ownership or use right of technology from others through patent transfer or patent license, it is also possible to transfer or license the patents developed by itself, so as to obtain higher profits.

In the competition of modern science and technology, whoever has the right to standard will win the right to speak and seize the opportunity for development. Otherwise, even if you master the core technology, you will not be able to occupy the high end of the value chain, and become an exporter or producer of raw materials, allowing others to take away high profits." This national health and health science and technology innovation work conference also pointed out the direction for the future development of Chinese pharmaceutical enterprises: give full play to the role of innovation subject, enhance the awareness of intellectual property protection, conduct in-depth research on the establishment of evaluation methods and standard system, and actively promote technology trading and intellectual property protection. For Chinese pharmaceutical companies, only by calculating the account of intellectual property rights can they move forward in the continuous expansion in the future.

News source:http://www.y-lp.com/pages/Article.aspx?id=4700289699138732195

This news was re-edited and reorganized by the Huaxun team and added analytical comments.